177 related articles for article (PubMed ID: 21537551)
41. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
[TBL] [Abstract][Full Text] [Related]
42. Allele and genotype frequencies of CYP2C9 in a Korean population.
Bae JW; Kim HK; Kim JH; Yang SI; Kim MJ; Jang CG; Park YS; Lee SY
Br J Clin Pharmacol; 2005 Oct; 60(4):418-22. PubMed ID: 16187974
[TBL] [Abstract][Full Text] [Related]
43. Influenza immunization does not predominantly alter levels of phenytoin, and cytochrome P-450 enzymes in epileptic patients receiving phenytoin monotherapy.
Soontornpun A; Manoyana N; Apaijai N; Pinyopornpanish K; Pinyopornpanish K; Nadsasarn A; Tanprawate S; Chattipakorn N; Chattipakorn SC
Epilepsy Res; 2020 Nov; 167():106471. PubMed ID: 33007725
[TBL] [Abstract][Full Text] [Related]
44. Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies.
Shintani M; Ieiri I; Inoue K; Mamiya K; Ninomiya H; Tashiro N; Higuchi S; Otsubo K
Clin Pharmacol Ther; 2001 Aug; 70(2):175-82. PubMed ID: 11503012
[TBL] [Abstract][Full Text] [Related]
45. Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients.
Hung CC; Huang HC; Gao YH; Chang WL; Ho JL; Chiou MH; Hsieh YW; Liou HH
Pharmacogenomics; 2012 Sep; 13(12):1339-49. PubMed ID: 22966884
[TBL] [Abstract][Full Text] [Related]
46. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
Hashimoto Y; Otsuki Y; Odani A; Takano M; Hattori H; Furusho K; Iui K
Biol Pharm Bull; 1996 Aug; 19(8):1103-5. PubMed ID: 8874828
[TBL] [Abstract][Full Text] [Related]
47. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population.
Burian M; Grösch S; Tegeder I; Geisslinger G
Br J Clin Pharmacol; 2002 Nov; 54(5):518-21. PubMed ID: 12445031
[TBL] [Abstract][Full Text] [Related]
48. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population.
Jose R; Chandrasekaran A; Sam SS; Gerard N; Chanolean S; Abraham BK; Satyanarayanamoorthy K; Peter A; Rajagopal K
Fundam Clin Pharmacol; 2005 Feb; 19(1):101-5. PubMed ID: 15660966
[TBL] [Abstract][Full Text] [Related]
49. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
[TBL] [Abstract][Full Text] [Related]
50. [Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics].
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Ned Tijdschr Geneeskd; 2001 Feb; 145(7):312-5. PubMed ID: 11234294
[TBL] [Abstract][Full Text] [Related]
51. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.
Zand N; Tajik N; Moghaddam AS; Milanian I
Clin Exp Pharmacol Physiol; 2007; 34(1-2):102-5. PubMed ID: 17201743
[TBL] [Abstract][Full Text] [Related]
52. The effect of polymorphic metabolism enzymes on serum phenytoin level.
Ozkaynakci A; Gulcebi MI; Ergeç D; Ulucan K; Uzan M; Ozkara C; Guney I; Onat FY
Neurol Sci; 2015 Mar; 36(3):397-401. PubMed ID: 25311916
[TBL] [Abstract][Full Text] [Related]
53. The association between CYP 2C9 polymorphism and bone health.
Phabphal K; Geater A; Limapichat K; Sathirapanya P; Setthawatcharawanich S; Leelawattana R
Seizure; 2013 Nov; 22(9):766-71. PubMed ID: 23849849
[TBL] [Abstract][Full Text] [Related]
54. Phenytoin intoxication induced by fluvoxamine.
Mamiya K; Kojima K; Yukawa E; Higuchi S; Ieiri I; Ninomiya H; Tashiro N
Ther Drug Monit; 2001 Feb; 23(1):75-7. PubMed ID: 11206048
[TBL] [Abstract][Full Text] [Related]
55. The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis
.
Liao K; Liu Y; Ai CZ; Yu X; Li W
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):337-346. PubMed ID: 29628024
[TBL] [Abstract][Full Text] [Related]
56. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
57. Allele and genotype frequency of CYP2C9 in Tamilnadu population.
Adithan C; Gerard N; Vasu S; Balakrishnan R; Shashindran CH; Krishnamoorthy R
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):707-9. PubMed ID: 14504850
[TBL] [Abstract][Full Text] [Related]
58. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.
López M; Dorado P; Monroy N; Alonso ME; Jung-Cook H; Machín E; Peñas-Lledó E; Llerena A
Drug Metabol Drug Interact; 2011; 26(1):5-12. PubMed ID: 21557672
[TBL] [Abstract][Full Text] [Related]
59. The clinical impact of pharmacogenetics on the treatment of epilepsy.
Löscher W; Klotz U; Zimprich F; Schmidt D
Epilepsia; 2009 Jan; 50(1):1-23. PubMed ID: 18627414
[TBL] [Abstract][Full Text] [Related]
60. Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction.
Citerio G; Nobili A; Airoldi L; Pastorelli R; Patruno A
Neurology; 2003 Apr; 60(8):1395-6. PubMed ID: 12707459
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
